GLP's ⏱ Half-life: ~7 days

Cagrilintide

Cagrilintide (NN9838, AM833)

Buy at SourcePeptides →
Half-Life
~7 days
Purity
Pharmaceutical grade (clinical trial material)
Mol. Weight
~4,000 Da
Form
Subcutaneous injection

What is Cagrilintide?

Cagrilintide represents a novel approach to obesity pharmacotherapy through amylin receptor agonism. Developed by Novo Nordisk, it is being positioned both as a standalone anti-obesity agent and as the amylin component of CagriSema, a fixed-ratio combination with semaglutide that targets two complementary appetite pathways.

Dosage Information (Research Use)

Clinical trial doses: 0.3mg to 4.5mg subcutaneously once weekly. Not yet commercially available. Investigational compound.

Reconstitution & Handling

Clinical trial formulation — pre-filled pen.

Half-Life & Pharmacokinetics

~7 days

Reported Observations in Literature

Nausea (22-47% dose-dependent), injection site reactions (4-26%), diarrhea, vomiting. GI side effects diminish with slow titration.

Key Research References

  • Lau DCW et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity.” Lancet. 2021;398:2160-72

How Cagrilintide Works

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other brainstem regions, producing potent appetite suppression, slowed gastric emptying, and reduced glucagon secretion through a pathway complementary to GLP-1.

Research Applications

🔬 Obesity treatment (monotherapy and combination)
🔬 Type 2 diabetes
🔬 CagriSema combination therapy

Research Findings

Phase 2 trials showed 10.8% weight loss at the highest dose (4.5mg weekly) over 26 weeks. The combination with semaglutide (CagriSema) achieved ~15.6% weight loss in early trials, suggesting additive benefit. Phase 3 REDEFINE trials are ongoing.

Dosage & Administration

Clinical trial doses: 0.3mg to 4.5mg subcutaneously once weekly. Not yet commercially available. Investigational compound.

Safety & Side Effects

Nausea (22-47% dose-dependent), injection site reactions (4-26%), diarrhea, vomiting. GI side effects diminish with slow titration.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight ~4,000 Da
Half-Life ~7 days
Purity Pharmaceutical grade (clinical trial material)
Form Subcutaneous injection
Storage Refrigerate 2-8°C.

Key Research References

  • Lau DCW et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." Lancet. 2021;398:2160-72

Get Cagrilintide from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Retatrutide
GLP's
Investigational triple-hormone receptor agonist (GIP/GLP-1/glucagon) showing potent metabolic effects in early clinical trials.
View Profile → Buy at SP →
Peptide YY
GLP's
Gut-derived satiety hormone that reduces appetite and regulates energy balance, with research implications for obesity treatment.
View Profile → Buy at SP →
Survodutide
GLP's
Dual GLP-1/glucagon receptor agonist in Phase 3 trials showing potent weight loss and liver fat reduction.
View Profile → Buy at SP →